Wren Therapeutics has recently completed an £18 million Series A financing round that will help accelerate the company’s pipeline for protein misfolding diseases.
The company began life in 2016 as a spin-out from the University of Cambridge in the UK and Sweden’s Lund University.
It has now raises £18 million during this round led by The Baupost Group with participation from LifeForce Capital and several individual investors described as “high net worth”.
“Protein misfolding diseases are one of the most critical global healthcare challenges of the 21st century but are highly complex and challenging to address,” said Samuel Cohen, one of Wren’s founders who will become permanent CEO.
“Current strategies – in particular those driven by traditional drug discovery and biological approaches – have proven, at least to date, to be ineffective.”
He added: “Wren’s new and unique approach is instead built on concepts from the physical sciences and focuses on the chemical kinetics of the protein misfolding process, creating a predictive and quantitatively driven platform that has the potential to radically advance drug discovery in this class of diseases.”